Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans
Summary We have recently introduced 125 I-hCG as an elimination marker in patients with human chorionic gonadotrophin (hCG) producing testicular cancer. 125 I-hCG is a well-known reagent in clinical biochemistry and is used extensively in hCG assays. Previous studies have shown that the iodination p...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1999-07, Vol.80 (10), p.1582-1587 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1587 |
|---|---|
| container_issue | 10 |
| container_start_page | 1582 |
| container_title | British journal of cancer |
| container_volume | 80 |
| creator | Christensen, T B Marqversen, J Engbaek, F Berger, P Bacher, T Maase, H von der |
| description | Summary
We have recently introduced
125
I-hCG as an elimination marker in patients with human chorionic gonadotrophin (hCG) producing testicular cancer.
125
I-hCG is a well-known reagent in clinical biochemistry and is used extensively in hCG assays. Previous studies have shown that the iodination process leaves the hCG molecule mainly intact. The iodination, purification and stability of
125
I-hCG tracer are described. The aim of the present study was to determine whether or not
125
I is associated with hCG after the injection of
125
I-hCG intravenously (i.v.) in humans. Three different methods were used. Following injection of
125
I-hCG, the plasma disappearance of radioactivity and hCG were followed for a period of 28 days in 13 normal subjects. Serum from a normal healthy male following injection of
125
I-hCG was analysed using a double antibody direct binding radioimmunoassay specific for holo-hCG and high performance liquid chromatography (HPLC). Following injection of
125
I-hCG in eight normal healthy males and five normal healthy females, the disappearance of radioactivity and hCG showed identical paths in the 28 days follow-up period. The bindable radioactive fraction of immunologically active hCG in serum of a normal healthy male following injection of
125
I-hCG was between 57.0% and 72.1%, and was constant over time. HPLC showed similar elution pattern of serum from a normal healthy male injected i.v. with
125
I-hCG and
125
I-hCG. Using three different methods, we were able concurrently to demonstrate the association of
125
I with hCG in humans up to 28 days after injection of radiolabelled hCG i.v. Thus, information about the expected elimination of hCG can be obtained by following the elimination of activity in plasma after injection of
125
I-hCG. |
| doi_str_mv | 10.1038/sj.bjc.6690566 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69892612</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3026-9007767f017e4d1ccc80861f7243ea9cd87a567d013286dd86538d578df3951e3</originalsourceid><addsrcrecordid>eNp1kUlPHDEQha0oURhIrjkiH6LcevDS7eWChEZhkZC4JLlaHi-MO9022N0j8e8xzIjlwKlk1_fqlf0A-IHREiMqTkq_XPdmyZhEHWOfwAJ3lDRYEP4ZLBBCvEGSoANwWEpfjxIJ_hUcYNQi0SK6APM_PQSrp5AiTB5i0l01m9UF1AVqOOr832XoU4ZuCGOIL9wzEi0sk16HIUwP78V-qrIQ4TZsU629M8_CerOZRx3LN_DF66G47_t6BP6e__6zumyuby6uVmfXjaGIsEbW_TnjHmHuWouNMQIJhj0nLXVaGiu47hi3CFMimLWCdVTYjgvrqeywo0fgdDf3bl6PzhoXp6wHdZdDfdqDSjqo950YNuo2bRWhjGKM64Bf-wE53c-uTGoMxbhh0NGluSgmhSQMkwoud6DJqZTs_IsJRuopKVV6VZNS-6Sq4Pjtam_wXTQV-LkHdDF68FlHE8orJ7hsyZPxyQ4rtRNvXVZ9mnOsv_qR8yPpF6r5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69892612</pqid></control><display><type>article</type><title>Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Christensen, T B ; Marqversen, J ; Engbaek, F ; Berger, P ; Bacher, T ; Maase, H von der</creator><creatorcontrib>Christensen, T B ; Marqversen, J ; Engbaek, F ; Berger, P ; Bacher, T ; Maase, H von der</creatorcontrib><description>Summary
We have recently introduced
125
I-hCG as an elimination marker in patients with human chorionic gonadotrophin (hCG) producing testicular cancer.
125
I-hCG is a well-known reagent in clinical biochemistry and is used extensively in hCG assays. Previous studies have shown that the iodination process leaves the hCG molecule mainly intact. The iodination, purification and stability of
125
I-hCG tracer are described. The aim of the present study was to determine whether or not
125
I is associated with hCG after the injection of
125
I-hCG intravenously (i.v.) in humans. Three different methods were used. Following injection of
125
I-hCG, the plasma disappearance of radioactivity and hCG were followed for a period of 28 days in 13 normal subjects. Serum from a normal healthy male following injection of
125
I-hCG was analysed using a double antibody direct binding radioimmunoassay specific for holo-hCG and high performance liquid chromatography (HPLC). Following injection of
125
I-hCG in eight normal healthy males and five normal healthy females, the disappearance of radioactivity and hCG showed identical paths in the 28 days follow-up period. The bindable radioactive fraction of immunologically active hCG in serum of a normal healthy male following injection of
125
I-hCG was between 57.0% and 72.1%, and was constant over time. HPLC showed similar elution pattern of serum from a normal healthy male injected i.v. with
125
I-hCG and
125
I-hCG. Using three different methods, we were able concurrently to demonstrate the association of
125
I with hCG in humans up to 28 days after injection of radiolabelled hCG i.v. Thus, information about the expected elimination of hCG can be obtained by following the elimination of activity in plasma after injection of
125
I-hCG.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6690566</identifier><identifier>PMID: 10408403</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Chorionic Gonadotropin - administration & dosage ; Chorionic Gonadotropin - blood ; Chromatography, High Pressure Liquid ; Drug Resistance ; Endocrine glands. Genital system. Mammary gland ; Epidemiology ; Female ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Iodine Radioisotopes ; Male ; Medical sciences ; Middle Aged ; Molecular Medicine ; Oncology ; Radionuclide investigations ; Reference Values ; Regular ; regular-article ; Reproducibility of Results</subject><ispartof>British journal of cancer, 1999-07, Vol.80 (10), p.1582-1587</ispartof><rights>The Author(s) 1999</rights><rights>1999 INIST-CNRS</rights><rights>Copyright © 1999 Cancer Research Campaign 1999 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3026-9007767f017e4d1ccc80861f7243ea9cd87a567d013286dd86538d578df3951e3</citedby><cites>FETCH-LOGICAL-c3026-9007767f017e4d1ccc80861f7243ea9cd87a567d013286dd86538d578df3951e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363111/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363111/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,41487,42556,51318,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1879422$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10408403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Christensen, T B</creatorcontrib><creatorcontrib>Marqversen, J</creatorcontrib><creatorcontrib>Engbaek, F</creatorcontrib><creatorcontrib>Berger, P</creatorcontrib><creatorcontrib>Bacher, T</creatorcontrib><creatorcontrib>Maase, H von der</creatorcontrib><title>Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Summary
We have recently introduced
125
I-hCG as an elimination marker in patients with human chorionic gonadotrophin (hCG) producing testicular cancer.
125
I-hCG is a well-known reagent in clinical biochemistry and is used extensively in hCG assays. Previous studies have shown that the iodination process leaves the hCG molecule mainly intact. The iodination, purification and stability of
125
I-hCG tracer are described. The aim of the present study was to determine whether or not
125
I is associated with hCG after the injection of
125
I-hCG intravenously (i.v.) in humans. Three different methods were used. Following injection of
125
I-hCG, the plasma disappearance of radioactivity and hCG were followed for a period of 28 days in 13 normal subjects. Serum from a normal healthy male following injection of
125
I-hCG was analysed using a double antibody direct binding radioimmunoassay specific for holo-hCG and high performance liquid chromatography (HPLC). Following injection of
125
I-hCG in eight normal healthy males and five normal healthy females, the disappearance of radioactivity and hCG showed identical paths in the 28 days follow-up period. The bindable radioactive fraction of immunologically active hCG in serum of a normal healthy male following injection of
125
I-hCG was between 57.0% and 72.1%, and was constant over time. HPLC showed similar elution pattern of serum from a normal healthy male injected i.v. with
125
I-hCG and
125
I-hCG. Using three different methods, we were able concurrently to demonstrate the association of
125
I with hCG in humans up to 28 days after injection of radiolabelled hCG i.v. Thus, information about the expected elimination of hCG can be obtained by following the elimination of activity in plasma after injection of
125
I-hCG.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Chorionic Gonadotropin - administration & dosage</subject><subject>Chorionic Gonadotropin - blood</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Drug Resistance</subject><subject>Endocrine glands. Genital system. Mammary gland</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Iodine Radioisotopes</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Radionuclide investigations</subject><subject>Reference Values</subject><subject>Regular</subject><subject>regular-article</subject><subject>Reproducibility of Results</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp1kUlPHDEQha0oURhIrjkiH6LcevDS7eWChEZhkZC4JLlaHi-MO9022N0j8e8xzIjlwKlk1_fqlf0A-IHREiMqTkq_XPdmyZhEHWOfwAJ3lDRYEP4ZLBBCvEGSoANwWEpfjxIJ_hUcYNQi0SK6APM_PQSrp5AiTB5i0l01m9UF1AVqOOr832XoU4ZuCGOIL9wzEi0sk16HIUwP78V-qrIQ4TZsU629M8_CerOZRx3LN_DF66G47_t6BP6e__6zumyuby6uVmfXjaGIsEbW_TnjHmHuWouNMQIJhj0nLXVaGiu47hi3CFMimLWCdVTYjgvrqeywo0fgdDf3bl6PzhoXp6wHdZdDfdqDSjqo950YNuo2bRWhjGKM64Bf-wE53c-uTGoMxbhh0NGluSgmhSQMkwoud6DJqZTs_IsJRuopKVV6VZNS-6Sq4Pjtam_wXTQV-LkHdDF68FlHE8orJ7hsyZPxyQ4rtRNvXVZ9mnOsv_qR8yPpF6r5</recordid><startdate>19990701</startdate><enddate>19990701</enddate><creator>Christensen, T B</creator><creator>Marqversen, J</creator><creator>Engbaek, F</creator><creator>Berger, P</creator><creator>Bacher, T</creator><creator>Maase, H von der</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19990701</creationdate><title>Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans</title><author>Christensen, T B ; Marqversen, J ; Engbaek, F ; Berger, P ; Bacher, T ; Maase, H von der</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3026-9007767f017e4d1ccc80861f7243ea9cd87a567d013286dd86538d578df3951e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Chorionic Gonadotropin - administration & dosage</topic><topic>Chorionic Gonadotropin - blood</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Drug Resistance</topic><topic>Endocrine glands. Genital system. Mammary gland</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Iodine Radioisotopes</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Radionuclide investigations</topic><topic>Reference Values</topic><topic>Regular</topic><topic>regular-article</topic><topic>Reproducibility of Results</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Christensen, T B</creatorcontrib><creatorcontrib>Marqversen, J</creatorcontrib><creatorcontrib>Engbaek, F</creatorcontrib><creatorcontrib>Berger, P</creatorcontrib><creatorcontrib>Bacher, T</creatorcontrib><creatorcontrib>Maase, H von der</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Christensen, T B</au><au>Marqversen, J</au><au>Engbaek, F</au><au>Berger, P</au><au>Bacher, T</au><au>Maase, H von der</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1999-07-01</date><risdate>1999</risdate><volume>80</volume><issue>10</issue><spage>1582</spage><epage>1587</epage><pages>1582-1587</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Summary
We have recently introduced
125
I-hCG as an elimination marker in patients with human chorionic gonadotrophin (hCG) producing testicular cancer.
125
I-hCG is a well-known reagent in clinical biochemistry and is used extensively in hCG assays. Previous studies have shown that the iodination process leaves the hCG molecule mainly intact. The iodination, purification and stability of
125
I-hCG tracer are described. The aim of the present study was to determine whether or not
125
I is associated with hCG after the injection of
125
I-hCG intravenously (i.v.) in humans. Three different methods were used. Following injection of
125
I-hCG, the plasma disappearance of radioactivity and hCG were followed for a period of 28 days in 13 normal subjects. Serum from a normal healthy male following injection of
125
I-hCG was analysed using a double antibody direct binding radioimmunoassay specific for holo-hCG and high performance liquid chromatography (HPLC). Following injection of
125
I-hCG in eight normal healthy males and five normal healthy females, the disappearance of radioactivity and hCG showed identical paths in the 28 days follow-up period. The bindable radioactive fraction of immunologically active hCG in serum of a normal healthy male following injection of
125
I-hCG was between 57.0% and 72.1%, and was constant over time. HPLC showed similar elution pattern of serum from a normal healthy male injected i.v. with
125
I-hCG and
125
I-hCG. Using three different methods, we were able concurrently to demonstrate the association of
125
I with hCG in humans up to 28 days after injection of radiolabelled hCG i.v. Thus, information about the expected elimination of hCG can be obtained by following the elimination of activity in plasma after injection of
125
I-hCG.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>10408403</pmid><doi>10.1038/sj.bjc.6690566</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1999-07, Vol.80 (10), p.1582-1587 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363111 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Adult Biological and medical sciences Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Cancer Research Chorionic Gonadotropin - administration & dosage Chorionic Gonadotropin - blood Chromatography, High Pressure Liquid Drug Resistance Endocrine glands. Genital system. Mammary gland Epidemiology Female Humans Investigative techniques, diagnostic techniques (general aspects) Iodine Radioisotopes Male Medical sciences Middle Aged Molecular Medicine Oncology Radionuclide investigations Reference Values Regular regular-article Reproducibility of Results |
| title | Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T11%3A05%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20125I-hCG%20as%20a%20marker%20for%20elimination%20of%20hCG%20and%20stability%20of%20125I-hCG%20after%20in%20vivo%20injection%20in%20humans&rft.jtitle=British%20journal%20of%20cancer&rft.au=Christensen,%20T%20B&rft.date=1999-07-01&rft.volume=80&rft.issue=10&rft.spage=1582&rft.epage=1587&rft.pages=1582-1587&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6690566&rft_dat=%3Cproquest_pubme%3E69892612%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69892612&rft_id=info:pmid/10408403&rfr_iscdi=true |